Press Releases

Press Releases

    Date Title View
    02/18/20
    Summary ToggleHorizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
    PDF Version
    02/18/20
    Summary ToggleHorizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules
    PDF Version
    02/11/20
    Summary ToggleUplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine
    PDF Version
    02/04/20
    Summary ToggleHorizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020
    PDF Version
    01/28/20
    Summary ToggleHorizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations
    PDF Version
    01/24/20
    Summary ToggleHorizon Therapeutics plc Announces Changes in Research and Development Organization
    PDF Version
    01/22/20
    Summary ToggleThe New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
    PDF Version
    01/21/20
    Summary ToggleFDA Approves TEPEZZA (TM) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
    PDF Version
    01/13/20
    Summary ToggleHorizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs
    PDF Version
    01/13/20
    Summary ToggleMIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
    PDF Version
    Displaying 1 - 10 of 488 results